You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
廣生堂(300436.SZ):久哥他達拉非片獲得藥品批准文號
格隆匯 04-13 18:02

格隆匯4月13日丨廣生堂(300436.SZ)公佈,近日,公司從國家藥品監督管理局官網網站獲悉公司他達拉非片已通過審批並獲得藥品批准文號,待領取藥品批准文件。他達拉非片的獲批進一步豐富了公司產品種類,為公司提供新的利潤增長點,以仿哺創,助力公司創新轉型發展。

他達拉非片是治療勃起功能障礙(簡稱“ED”)的兩大主流藥物之一。米內網數據顯示,2020年他達拉非在中國城市公立醫院、縣級公立醫院、城市社區中心及鄉鎮衞生院終端和中國城市實體藥店終端的銷售額超8億元,其中中國城市實體藥店終端的銷售佔比接近90%。

公司表示,獲得他達拉非片藥品批准文號,視同通過一致性評價,進一步豐富了公司的產品種類,有利於提升公司的市場競爭力,增強公司零售產品管線,與勁哥枸緣酸西地那非片協同,為消費者提供更多選擇,也為公司帶來新的利潤增長點,以仿哺創,助力公司創新轉型發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account